The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jul 2017
Randomized Controlled TrialEffect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients. ⋯ This study does not support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-associated angioedema.
-
J. Allergy Clin. Immunol. · Jul 2017
Randomized Controlled Trial Multicenter StudyA randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Few data are available to assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab. ⋯ Continuation of omalizumab after long-term treatment results in continued benefit, as evidenced by improved symptom control and reduced exacerbation risk.
-
J. Allergy Clin. Immunol. · Jul 2017
Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations.
Ikaros, which is encoded by IKZF1, is a transcriptional factor that play a critical role in hematopoiesis. Somatic IKZF1 alterations are known to be involved in the pathogenesis of leukemia in human subjects. Recently, immunodeficiency caused by germline IKZF1 mutation has been described. ⋯ Germline heterozygous IKZF1 mutations cause dysgammaglobulinemia; hematologic abnormalities, including B-cell defect; and autoimmune diseases.
-
J. Allergy Clin. Immunol. · Jul 2017
Controlled Clinical TrialGroup 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. ⋯ ILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD, correlating with enhanced production of prostaglandins and leukotrienes.
-
J. Allergy Clin. Immunol. · Jun 2017
The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis.
Idiopathic pulmonary fibrosis (IPF) is progressive and rapidly fatal. Improved understanding of pathogenesis is required to prosper novel therapeutics. Epigenetic changes contribute to IPF; therefore, microRNAs may reveal novel pathogenic pathways. ⋯ We describe herein a molecular pathway comprising miR-155 and its epigenetic LXRα target that when deregulated enables pathogenic pulmonary fibrosis. Manipulation of the miR-155/LXR pathway may have therapeutic potential for IPF.